Poor
Not Aligned
Patient Risk:
Moderate
Summary
The response makes several general, label-unsupported comparisons between Tepmetko and Tabrecta (mechanism, side-effect overlap, biomarker eligibility, and selection criteria) using information not present in the provided TEPMETKO label excerpts. It also omits key TEPMETKO-specific labeled details needed for eligibility and safety discussions.
Category Scores
Accurate Statements
Tepmetko (tepotinib) and Tabrecta (capmatinib) are targeted cancer drugs used for MET-driven disease.
Only TEPMETKO excerpt provided is indication for MET exon 14 skipping alterations; no Tabrecta label content was provided. Partial support at most for TEPMETKO being MET-related, but Tabrecta and 'MET-driven disease' for both are not supported by provided TEPMETKO-only excerpts.
Unsupported Statements
Tepmetko and Tabrecta both inhibit the MET (mesenchymal-epithelial transition) signaling pathway.
No provided label excerpt states Tabrecta’s mechanism or that both drugs inhibit MET in the way described.
Tepmetko and Tabrecta share the mechanism of MET inhibition.
Mechanism comparison between tepotinib and capmatinib is not supported by the provided TEPMETKO label excerpts.
Differences between Tepmetko and Tabrecta include how each drug binds and how it behaves in the body.
No binding/PK comparative statements for Tabrecta or direct comparison are present in the provided TEPMETKO excerpts.
Patients are typically selected based on whether their tumor has MET alterations consistent with each drug’s approved or indicated use.
The provided TEPMETKO excerpt supports selection based on MET exon 14 skipping alterations, but the statement is generalized to 'each drug' (including Tabrecta) and is not supported for Tabrecta.
In general terms, both drugs are used when MET is the driver, such as in cases of MET exon 14 skipping or other MET-dependent biomarkers.
The provided TEPMETKO label excerpt limits indication to metastatic NSCLC harboring MET exon 14 skipping alterations; no provided label content supports use for 'other MET-dependent biomarkers' or for Tabrecta.
The exact eligibility details for use are tied to each drug’s labeled indication and trial criteria.
General statement about Tabrecta eligibility/trial criteria is not supported because Tabrecta label/criteria are not provided.
Some adverse events can overlap between Tepmetko and Tabrecta because they target the same pathway.
No Tabrecta adverse event profile is provided, and the 'because they target the same pathway' causal rationale is not supported by the provided TEPMETKO excerpts.
Edema and other tolerability issues are examples of common class-type adverse events considered when choosing between MET inhibitors.
No label excerpt provided supports 'class-type' comparisons across MET inhibitors or explicitly links edema to both drugs in a comparative way.
What changes from drug to drug includes the mix of side effects, their frequency, and their severity.
General comparative statement not supported by the provided TEPMETKO excerpts (especially without Tabrecta safety data).
There is no single 'always better' answer when choosing between Tepmetko and Tabrecta for a given patient.
Not a label-supported claim in the provided excerpts; also not tied to specific TEPMETKO-labeled selection or safety guidance.
The practical choice between Tepmetko and Tabrecta depends on the specific MET biomarker status used to qualify the patient.
TEPMETKO requires MET exon 14 skipping alterations, but the claim is comparative ('between Tepmetko and Tabrecta') and Tabrecta-specific biomarker selection is not supported.
The practical choice between Tepmetko and Tabrecta depends on the drug’s dosing and scheduling.
Tabrecta dosing/scheduling is not provided; TEPMETKO label dosing excerpt does not justify comparative dosing/scheduling decision-making.
The practical choice between Tepmetko and Tabrecta depends on the patient’s other health conditions and risk factors for known adverse events.
TEPMETKO label includes monitoring for specific toxicities, but the comparative 'risk factors for known adverse events' across both drugs is not supported without Tabrecta label content.
The practical choice between Tepmetko and Tabrecta depends on how a patient has tolerated prior therapy, if any.
No TEPMETKO labeling excerpt provided supports this comparative treatment-history selection rationale.
Clinician judgment based on labeled indications and available evidence affects the choice between Tepmetko and Tabrecta.
General statement not supported by label excerpts; label provided does not discuss comparative prescribing between TEPMETKO and TABRECTA.
Access and pricing can vary by product.
Not information contained in the provided prescribing information excerpts.
Contradictions
Important Omissions
TEPMETKO-specific dosing and administration details (e.g., recommended dosage 450 mg orally once daily with food, and continuation until progression/unacceptable toxicity) are not described despite the response discussing dosing/scheduling as a decision factor between drugs.
Importance:
Moderate
TEPMETKO label patient selection/testing specifics (select patients with MET exon 14 skipping alterations in plasma or tumor; plasma testing recommended only if biopsy cannot be obtained; no FDA-approved test available) are not accurately incorporated into the comparative eligibility discussion.
Importance:
Moderate
Key TEPMETKO labeled warnings/monitoring (e.g., ILD/pneumonitis with withholding/discontinuation logic; hepatotoxicity monitoring schedule; pancreatic toxicity monitoring) are not mentioned, despite the response implying comparative tolerability and safety-profile differences.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response suggests comparative selection based on MET-driven disease and tolerability overlaps without providing TEPMETKO-specific labeled selection/testing and monitoring details. This increases the chance of using incomplete or overly generalized safety/eligibility criteria.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Major portions of the response make comparative claims about Tabrecta and cross-drug mechanisms/adverse event overlap that are not supported by the provided TEPMETKO prescribing information excerpts.
Suggested Improvement
Limit statements to TEPMETKO-labeled content provided: metastatic NSCLC with MET exon 14 skipping alterations in adults, TEPMETKO patient selection/testing specifics, and TEPMETKO-specific dosage and monitoring (ILD/pneumonitis, hepatotoxicity, pancreatic toxicity). Avoid cross-drug comparisons (Tabrecta) unless Tabrecta label text is supplied and evaluated.